Similar articles

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

  Hwang EC, Gandhi S, Jung JH, Imamura M, Kim MH, Pang R, Dahm P. Hwang EC, et al. Cochrane Database Syst Rev. 2018 Oct 11;10(10):CD007360. doi: 10.1002/14651858.CD007360.pub3. Cochrane Database Syst Rev. 2018. PMID: 30306544 Free PMC article.
• A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

  Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. Manjunatha R, et al. Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825. Indian J Pharmacol. 2016. PMID: 27127315 Free PMC article. Clinical Trial.
• New alpha blockers to treat male lower urinary tract symptoms.

  Hwang EC, Gandhi S, Jung JH. Hwang EC, et al. Curr Opin Urol. 2018 May;28(3):273-276. doi: 10.1097/MOU.0000000000000488. Curr Opin Urol. 2018. PMID: 29613909
• Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.

  Tsumura H, Satoh T, Ishiyama H, Tabata K, Kotani S, Minamida S, Kimura M, Fujita T, Matsumoto K, Kitano M, Hayakawa K, Baba S. Tsumura H, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92. doi: 10.1016/j.ijrobp.2011.04.026. Epub 2011 Jun 12. Int J Radiat Oncol Biol Phys. 2011. PMID: 21664068 Clinical Trial.
• Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.

  Ichihara K, Masumori N, Iwasawa A, Taguchi K, Yamaguchi Y, Nishimura M, Sasamura H, Suzuki N, Haga K, Miyao N, Hirose T. Ichihara K, et al. Int J Urol. 2018 Oct;25(10):849-854. doi: 10.1111/iju.13757. Epub 2018 Aug 1. Int J Urol. 2018. PMID: 30066966